279 related articles for article (PubMed ID: 35603147)
1. Case Report: Two Cases of Soft-Tissue Sarcomas: High TMB as a Potential Predictive Biomarker for Anlotinib Combined With Toripalimab Therapy.
Li Y; Liu Y; Qu Y; Chen X; Qu X; Ye Y; Du X; Cheng Y; Xu M; Zhang H
Front Immunol; 2022; 13():832593. PubMed ID: 35603147
[TBL] [Abstract][Full Text] [Related]
2. Activity of PD-1 Inhibitor Combined With Anti-Angiogenic Therapy in Advanced Sarcoma: A Single-Center Retrospective Analysis.
You Y; Guo X; Zhuang R; Zhang C; Wang Z; Shen F; Wang Y; Liu W; Zhang Y; Lu W; Hou Y; Wang J; Zhang X; Lu M; Zhou Y
Front Mol Biosci; 2021; 8():747650. PubMed ID: 34869583
[No Abstract] [Full Text] [Related]
3. Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma.
Jiang M; Zhang C; Hu Y; Li T; Yang G; Wang G; Zhu J; Shao C; Hou H; Zhou N; Liu K; Zhang X
Oncologist; 2022 Nov; 27(11):e856-e869. PubMed ID: 35857405
[TBL] [Abstract][Full Text] [Related]
4. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432.
Wang F; Wei XL; Wang FH; Xu N; Shen L; Dai GH; Yuan XL; Chen Y; Yang SJ; Shi JH; Hu XC; Lin XY; Zhang QY; Feng JF; Ba Y; Liu YP; Li W; Shu YQ; Jiang Y; Li Q; Wang JW; Wu H; Feng H; Yao S; Xu RH
Ann Oncol; 2019 Sep; 30(9):1479-1486. PubMed ID: 31236579
[TBL] [Abstract][Full Text] [Related]
5. Comparative Combinatorial Implications and Theranostics of Immunotherapy in the Impediment of Alveolar Soft Part Sarcoma.
Yang Y; Beeraka NM; Liu J; Zuo X; Wang X; Li T; Fan R
Curr Pharm Des; 2022; 28(41):3404-3412. PubMed ID: 36154597
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review.
Wu S; Wu S; Liao X; Zhou C; Qiu F; Wang C; Zhong W
Front Immunol; 2023; 14():1274937. PubMed ID: 37936698
[TBL] [Abstract][Full Text] [Related]
7. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
8. Next generation sequencing predicting clinical effect of immunotherapy on adult rhabdomyosarcoma patient: A case report.
Sun X; Wang X; Zhou J; Xu Y; Zhang H; Xu M; Shen J; Shi X; Song W; Li J
Medicine (Baltimore); 2023 May; 102(21):e33858. PubMed ID: 37233406
[TBL] [Abstract][Full Text] [Related]
9. Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03.
Sheng X; Chen H; Hu B; Yao X; Liu Z; Yao X; Guo H; Hu Y; Ji Z; Luo H; Shi B; Liu J; Wu J; Zhou F; He Z; Fan J; Wang W; Feng H; Yao S; Keegan P; Huang Y; Guo J
Clin Cancer Res; 2022 Feb; 28(3):489-497. PubMed ID: 34740921
[TBL] [Abstract][Full Text] [Related]
10. Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma.
Liu J; Gao T; Tan Z; Li S; Xu J; Bai C; Xue R; Xie L; Zhang L; Fan Z; Guo W
Clin Cancer Res; 2022 Aug; 28(16):3473-3479. PubMed ID: 35675031
[TBL] [Abstract][Full Text] [Related]
11. Combined immunotherapy and targeted treatment for primary alveolar soft part sarcoma of the lung: case report and literature review.
Su H; Yu C; Ma X; Song Q
Invest New Drugs; 2021 Oct; 39(5):1411-1418. PubMed ID: 33765213
[TBL] [Abstract][Full Text] [Related]
12. Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures.
Cheung LS; Chen L; Oke TF; Schaffer TB; Boudadi K; Ngo JT; Gross JM; Kemberling H; Diaz LA; Lipson E; Sidhom JW; Taube J; Anders R; Pardoll DM; Le DT; Meyer CF; Llosa N
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34103354
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive genomic analysis of primary bone sarcomas reveals different genetic patterns compared with soft tissue sarcomas.
Zhang Q; Yang Y; You X; Ju Y; Zhang Q; Sun T; Liu W
Front Oncol; 2023; 13():1173275. PubMed ID: 37546405
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma.
Chi Y; Fang Z; Hong X; Yao Y; Sun P; Wang G; Du F; Sun Y; Wu Q; Qu G; Wang S; Song J; Yu J; Lu Y; Zhu X; Niu X; He Z; Wang J; Yu H; Cai J
Clin Cancer Res; 2018 Nov; 24(21):5233-5238. PubMed ID: 29895706
[No Abstract] [Full Text] [Related]
15. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
[TBL] [Abstract][Full Text] [Related]
16. PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials.
Italiano A; Bellera C; D'Angelo S
J Hematol Oncol; 2020 May; 13(1):55. PubMed ID: 32430039
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of advanced pulmonary sarcomatoid carcinoma with the PD-1 inhibitor toripalimab: A case report.
Jiao Y; Liu M; Luo N; Guo H; Li J
Oral Oncol; 2021 Jan; 112():104992. PubMed ID: 32943323
[TBL] [Abstract][Full Text] [Related]
18. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.
Roulleaux Dugage M; Nassif EF; Italiano A; Bahleda R
Front Immunol; 2021; 12():775761. PubMed ID: 34925348
[TBL] [Abstract][Full Text] [Related]
19. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Genomic Profiling of Rare Tumors in China: Routes to Immunotherapy.
Wang S; Fang Y; Jiang N; Xing S; Li Q; Chen R; Yi X; Zhang Z; Li N
Front Immunol; 2021; 12():631483. PubMed ID: 33732253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
